Novartis AG - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US66987V1098

SecurityNVS / Novartis AG - Depositary Receipt (Common Stock)
InstitutionMercer Global Advisors Inc /adv
Latest Disclosed Ownership160,764 shares
Latest Disclosed Value $ 24,556,759
Mercer Global Advisors Inc /adv reports 2.95% increase in ownership of NVS / Novartis AG - Depositary Receipt (Common Stock)

On May 15, 2026 - Mercer Global Advisors Inc /adv filed a 13F-HR form disclosing ownership of 160,764 shares of Novartis AG - Depositary Receipt (Common Stock) (US:NVS) valued at $24,556,701 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 156,158 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of 2.95% during the quarter. The current value of the position is $23,979,558 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NOVARTIS SPONSORED ADR 66987V109 160,764 4,606 2.95 24,557 1.99 0.0363
2026-02-17 2025-12-31 13F NOVARTIS SPONSORED ADR 66987V109 156,158 19,787 14.51 24,079 37.68 0.0367
2025-11-14 2025-09-30 13F NOVARTIS SPONSORED ADR 66987V109 136,371 1,465 1.09 17,488 7.11 0.0292
2025-08-14 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 134,906 -7,101 -5.00 16,327 3.19 0.0333
2025-05-15 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 142,007 -3,752 -2.57 15,823 11.56 0.0363
2025-02-14 2024-12-31 13F NOVARTIS SPONSORED ADR 66987V109 145,759 -2,411 -1.63 14,184 -16.47 0.0346
2024-11-14 2024-09-30 13F NOVARTIS SPONSORED ADR 66987V109 148,170 -4,885 -3.19 16,980 16.79 0.0397
2024-08-12 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 153,055 5,285 3.58 14,539 103,750.00 0.0396
2024-05-15 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 147,770 36,704 33.05 14 27.27 0.0406
2024-02-15 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 111,066 2,851 2.63 11 0.00 0.0337
2023-11-15 2023-09-30 13F/A-1 NOVARTIS SPONSORED ADR 66987V109 108,215 6,046 5.92 11 10.00 0.0419
2023-11-14 2023-09-30 13F NOVARTIS SPONSORED ADR 66987V109 108,215 6,046 11 0.0418
2023-08-14 2023-06-30 13F NOVARTIS SPONSORED ADR 66987V109 102,169 10,151 11.03 10 25.00 0.0409
2023-05-16 2023-03-31 13F NOVARTIS SPONSORED ADR 66987V109 92,018 -4,258 -4.42 8 0.00 0.0385
2023-02-09 2022-12-31 13F NOVARTIS SPONSORED ADR 66987V109 96,276 -527 -0.54 9 -99.89 0.0437
2022-11-15 2022-09-30 13F NOVARTIS SPONSORED ADR 66987V109 96,803 2,239 2.37 7,358 -7.94 0.0437
2022-08-10 2022-06-30 13F NOVARTIS SPONSORED ADR 66987V109 94,564 14,190 17.65 7,993 13.33 0.0489
2022-05-10 2022-03-31 13F NOVARTIS SPONSORED ADR 66987V109 80,374 24,334 43.42 7,053 43.88 0.0415
2022-02-04 2021-12-31 13F NOVARTIS SPONSORED ADR 66987V109 56,040 3,634 6.93 4,902 14.37 0.0303
2021-11-10 2021-09-30 13F NOVARTIS SPONSORED ADR 66987V109 52,406 11,183 27.13 4,286 13.96 0.0299
2021-08-10 2021-06-30 13F NOVARTIS SPONSORED ADR 66987V109 41,223 -4,370 -9.58 3,761 -3.51 0.0289
2021-08-10 2021-03-31 13F/A-1 NOVARTIS SPONSORED ADR 66987V109 45,593 -6,504 -12.48 3,898 -20.77 0.0355
2021-05-11 2021-03-31 13F NOVARTIS SPONSORED ADR 66987V109 44,868 -7,229 3,836 0.0367
2021-02-12 2020-12-31 13F NOVARTIS SPONSORED ADR 66987V109 52,097 185 0.36 4,920 8.99 0.0614
2020-12-10 2020-09-30 13F NOVARTIS SPONSORED ADR 66987V109 51,912 -31,722 -37.93 4,514 -38.21 0.0679
2020-08-10 2020-06-30 13F NOVARTIS A G SPONSORED 66987V109 83,634 1,713 2.09 7,305 8.16 0.1326
2020-05-18 2020-03-31 13F NOVARTIS A G SPONSORED 66987V109 81,921 14,901 22.23 6,754 6.43 0.1486
2020-02-13 2019-12-31 13F NOVARTIS A G SPONSORED ADR COM 66987V109 67,020 1,272 1.93 6,346 11.08 0.1267
2019-11-12 2019-09-30 13F NOVARTIS A G SPONSORED ADR COM 66987V109 65,748 4,245 6.90 5,713 1.73 0.1344
2019-08-14 2019-06-30 13F NOVARTIS A G SPONSORED ADR COM 66987V109 61,503 12,066 24.41 5,616 18.16 0.1489
2019-04-23 2019-03-31 13F/A-1 NOVARTIS A G SPONSORED ADR COM 66987V109 49,437 49,437 4,753 0.1709
2019-04-12 2019-03-31 13F NOVARTIS A G SPONSORED A COM 66987V109 43,253 3,712 0.1978
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.